Rosacea Therapeutics Market
Market Study on Rosacea Therapeutics: Antibiotics to Remain Most-preferred Drug Class
Rosacea Treatment Market Segmented By Antimicrobials, Alpha agonists, Retinoid Drugs in Institutional Sales, and Retail sales
Rosacea Therapeutics Market Outlook (2022-2032)
The global rosacea therapeutics market reached a valuation of US$ 3.94 Bn in 2021. Demand for rosacea therapeutic delivery systems and drugs is predicted to expand at a CAGR of 6.2% to reach US$ 7.61 Bn by the year 2032.
Rosacea Therapeutics Market Size (2021)
US$ 3.94 Bn
Projected Market Value (2032)
US$ 7.61 Bn
Global Market Growth Rate (2022-2032)
Market Share of Top 5 Countries
As per detailed industry analysis by Persistence Market Research, oral antibiotics are expected to drive high market growth after holding a market share of 29.3% in 2021. Rosacea therapeutics accounted for a share of 10% in the global dermatology drugs market in 2021.
Find Out More about the Report Coverage
- Lupin Ltd
- Dr. Reddy's Laboratories Ltd
- VIATRIS (Mylan N.V.)
- Ajanta Pharma Ltd
- Cipla Ltd
- Gary Pharmaceuticals P Limited
- Glenmark Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Mission Pharmacal
- Sanofi SA
- VYNE Therapeutics
- Bayer AG
- Bausch Health Companies Inc.
- PruGen Pharmaceuticals
- AbbVie, Inc.
- Eckson Labs
- Sandoz Spa
- Abigail Care Pharmaceutical
- Pfizer Inc.
- Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
Demand Analysis of Rosacea Therapeutics from 2017 to 2021 Vs Market Outlook for 2022 to 2032
The global rosacea treatment drugs market expanded at a CAGR of 5.6% over the last five years (2017-2021).
As indicated by the Centres for Disease Control and Prevention and as per 2021 OECD Health Statistics, per capita medical services spending increase by around 4.9% in 2020. This was essentially driven by state-run administrations distributing more conspicuous resources for prosperity, including creating medical care framework.
With the rising need for novel healthcare products and regulations that came into the picture, demand for rosacea therapeutic drugs delivery systems is expected to steadily rise over the coming years.
Rosacea is a typical skin condition portrayed by redness and apparent veins on the face. The nose and cheeks are the most impacted parts. The signs and side effects of rosacea are little, red, discharge-filled knocks that erupt intermittently. A large portion of patients experience eye dryness and blushed eyelids. Other side effects include augmented nose and thickening of the skin around the nose (rhinophyma).
Rosacea-trigger factors include spicy foods and hot drinks, alcohol, extreme differences in temperature, exercise, cosmetics, drugs that dilate blood vessels, including some blood pressure medications, and others. There has been rising exposure to these triggers owing to increased urbanization and industrialization. Rising use of cosmetics and a hypertensive population also drive rosacea incidence.
The global rosacea therapeutic drug delivery systems market is expected to expand at a CAGR of 6.2% and record sales worth US$ 7.61 Bn by the end of 2032.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
What is the Road Ahead for Rosacea Therapy?
“Need for More Effective Drugs for Rosacea Treatment”
With the growing rate of product adoption, the untapped rosacea therapeutics market will offer numerous beneficial opportunities for key players.
Available drug treatment options fulfill a short-term, palliative role, and are rarely used alone as a long-term therapy. Currently, antibiotics such as doxycycline and topical metronidazole or azelaic acid are the first-line agents in the treatment of rosacea. None of the available rosacea treatment drugs target the cause of the disease. Thus, there is an unmet medical need for more effective drugs targeting the root cause of the disease.
The research and development pipeline of rosacea therapeutics is comparatively weak as compared to other diseases. Thus, a large gap exists between demand and the current therapies.
The NRS (National Rosacea Society's) research awards program has granted more than US$ 1.6 Mn to help 75 examinations, including logical examinations that have drawn an obvious conclusion in the provocative cycle, a critical hidden factor in the confusion. This commencement can attract many researchers and scientists in developing new medicines for rosacea treatment.
Growing research & development expenditure by companies is one of the major market opportunities owing to technological gains and the shorter time and resources needed to market products owing to low elasticity of demand. Low treatment rates of rosacea present another major market opportunity.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
Which Factors Can Dent Demand Growth of Rosacea Therapeutics?
“Non-life-threatening Nature of Rosacea & Poor Efficacy of Treatment Options”
Rosacea is generally not life-threatening, although cutaneous dissemination may occur, which results in high elasticity of demand. Treatment rates of rosacea are low, as most individuals suffering from rosacea use nothing at all for the condition or are notoriously non-adherent, probably because they consider the treatment ineffective.
Lack of effective diagnostic tests is another restraint for the rosacea treatment products market, resulting in false negatives.
Poor efficacy of treatment and the non-life-threatening nature of rosacea has resulted in large competition from alternative treatments, which are often not effective. Rosacea patients use a large assortment of non-prescription skincare products, including mild cleansers, moisturizers, and sunscreens, which drives down the market for rosacea therapeutics.
Side-effects associated with the usage of antibiotics can also lead to gastric discomfort, which includes nausea, gastritis, bloating and indigestion, loss of appetite, and abdominal pain.
Explore Persistence Market Research’s expertise in promulgation of the business !
Why is the U.S. a Prominent Market for Rosacea Therapeutics?
“High Awareness about Rosacea and its Treatment”
In 2021, the U.S. dominated the North America rosacea therapeutics market with over 91% market share. In the U.S. there is a high level of awareness among patients as well as end users about rosacea and its several treatment options, which has significantly driven the uptake of rosacea therapeutic products in the country.
Additionally, according to the Centres for Disease Control and Prevention, almost 16 Mn people in the U.S. suffer from rosacea. Thus, increase in prevalence of rosacea is also one of the major reasons of driving demand for rosacea therapeutics in the U.S. market.
How is Demand for Rosacea Treatment Shaping Up in Germany?
“Huge Healthcare Expenditure Coupled with High Rate of Diagnosis & Treatment”
In terms of value share, Germany accounts for 36.9% of the Europe rosacea therapeutics market. High rate of treatment and diagnosis coupled with huge healthcare expenditure and various collaborations drive the Germany market.
- For instance, on 10 January 2020, Bayer and Azitra Inc., a clinical-stage medical dermatology biotech company, entered into a joint development agreement to for the identification and characterization of skin microbiome bacteria.
Furthermore, quality health services, growing aging population, and rising skin diseases are estimated propel demand growth of rosacea treatment products in Germany.
Will the Emerging Market of China Provide Lucrative Opportunities for Rosacea Treatment Providers?
“Rapidly Rising Incidence of Rosacea in China”
The China rosacea therapeutics market accounts for more than 50% of the East Asian market share. In 2021, the market in China was valued at US$ 350.4 Mn.
According to the Indian Journal of Dermatology, Venereology, and Leprology 2020, incidence of rosacea is rising in China, which is one of the most prominent factor boosting market growth in the country.
Which Type of Disease is Most Commonly Catered to in Rosacea Therapeutics?
“Erythematotelangiectatic Rosacea Most Commonly Occurring Disease Type”
Erythematotelangiectatic rosacea, a subtype of rosacea that is characterized by recurrent episodes of transient face erythema (flushing) and no transient, or chronic erythema, is most common.
This segment held the highest market share of around 35.4% in the year 2021, and is expected to expand at a CAGR of 6.8% over the forecast period (2022-2032).
Which Drug Class is Most Popular in this Market Space?
“Antibiotics - Most Preferred Rosacea Treatment Option”
Antibiotics drug class is the leading segment in this market, and is set to account for a market share of 39.5% and expand at a CAGR of 6.4% over the forecast period (2022-2032).
Antibiotics are the most commonly preferred drug class by physicians and doctors for early relief from the disease. The high demand for antibiotics in the treatment of rosacea is the main factor that leads to account for the highest market share.
Which Distribution Channel Will Benefit Market Players the Most?
“Retail Sales of Rosacea Treatment Drugs the Highest”
The retail sales segment accounted for 52.1% market share, by value, in 2021, and is expected to expand at a CAGR of 6.4% during the forecast period.
High availability of almost every antibiotic and easy access to these stores make this segment the most lucrative one as compared to others.
Impact of COVID-19 Crisis
With the onset of COVID-19, one of the most important elements affecting the rosacea treatment drugs’ supply chain and price increase was geographic location. Extended use of face masks increased the indications and symptoms of rosacea, which was the most prominent effect of the pandemic on the prevalence of rosacea. Excessive face mask use has been linked to an increase in the occurrence of symptoms in papulopustular and erythematotelangiectatic rosacea.
Companies are strategically focusing on enhancing the distribution of their products in high profit-making markets. Key market players are promoting their products at professional scientific meetings and conferences.
Additionally, key players are actively focusing on partnerships and collaborating with suppliers to have a strong position and also to expand access to rosacea treatment drugs for patients.
- On January 19, 2022, Lupin Ltd signed a partnership agreement with Shenzhen Foncoo Pharmaceutical Co. Ltd. for providing high-quality generic and complex generic medicines to patients around the world.
- In June 2021, Teva Pharmaceuticals Industries Ltd. announced the generic version of SOOLANTRA® (ivermectin) Cream, 1% for the treatment of inflammatory lesions of rosacea.
- On October 4, 2021, Cipla and Eli Lilly and Cipla Ltd. partnered for the purpose of product expansion.
Rosacea Therapeutics Industry Report Scope
Historical Data Available for
US$ Million for Value
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon Request
Key Segments in Rosacea Therapeutics Industry Survey
Rosacea Therapeutics Market by Disease Type:
- Erythematotelangiectatic Rosacea
- Papulopustular Rosacea
- Ocular Rosacea
- Phymatous Rosacea
Rosacea Therapeutics Market by Drug Class:
Rosacea Therapeutics Market by Treatment Type:
- Erythromycin/ Clarithromycin
- Topical Treatment
- Sodium Sulfacetamide
- Azelaic acid
- Steroid Creams
- Eye Drops and Lubricants
- Other Drugs Including Methotrexate and Ivermectin
- Laser therapy
Rosacea Therapeutics Market by Route of Administration:
- Oral Rosacea Treatment
- Topical Rosacea Treatment
Rosacea Therapeutics Market by Distribution Channel:
- Institutional Sales
- Specialty Clinics
- Academic and Research Institutes
- Retail Sales
- Retail Pharmacies
- Drug Stores
- Online Sales
Rosacea Therapeutics Market by Region:
- North America Rosacea Therapeutics Market
- Latin America Rosacea Therapeutics Market
- Europe Rosacea Therapeutics Market
- South Asia Rosacea Therapeutics Market
- East Asia Rosacea Therapeutics Market
- Oceania Rosacea Therapeutics Market
- Middle East & Africa Rosacea Therapeutics Market
- FAQs -
The global rosacea therapeutics market is currently valued at US$ 3.94 Bn, and is expected to grow 1.9X by 2032.
The rosacea therapeutics industry is set to witness a high growth rate of 6.2% over the forecast period and reach US$ 7.61 Bn by 2032.
Consumption of rosacea treatment drugs increased at the rate of 5.6% from 2017 to 2021.
Galderma, AbbVie, Inc., Pfizer Inc., Sanofi SA, Janssen Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd are key players manufacturing rosacea therapeutic drugs.
The U.S., China, Germany, Brazil, and Japan currently hold more than 50% global market share.
The North America market for rosacea therapeutics market is one of the fastest-growing markets globally, and accounted for US$ 1.28 Bn in 2021.
The Europe rosacea treatment market worth is expected to record a CAGR of 6.9% over the forecast period.
The China market held a share of 54.6% in East Asia in 2021, with Japan accounting for 28.3% market share.